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Abstract: The role of donor-specific antibodies (DSA) to human leukocyte antigens and the 
burden of antibody-mediated rejection (AMR) in lung transplantation remain enigmatic. Over 
the past several years, evidence has been emerging that humoral immunity plays an important 
role in the development of both acute and chronic lung allograft dysfunction (CLAD). Mul-
tiple case reports and case series have identified lung allograft recipients with clinical findings 
consistent with acute AMR. However, there is currently no widely accepted definition for AMR 
in lung transplantation, and this has been a significant barrier to furthering our understand-
ing of this form of rejection. Nonetheless, the development of DSA after transplantation has 
consistently been identified as an independent risk factor for persistent and high-grade acute 
cellular rejection and CLAD. This has raised the possibility that chronic AMR may be a distinct 
phenotype of CLAD although evidence supporting this paradigm is still lacking. Additionally, 
antibodies to lung-restricted self-antigens (collagen V and K-α 1 tubulin) have been associated 
with primary graft dysfunction early and the development of CLAD late after transplantation, 
and emerging evidence underscores significant interactions between autoimmunity and alloim-
munity after transplantation. There is currently an active International Society for Heart and 
Lung Transplantation working group that is developing an operational definition for AMR in 
lung transplantation. This will be critical to improve our understanding of this form of rejection 
and conduct clinical trials to identify optimal treatment strategies. This review will summarize 
the literature on DSA and AMR in lung transplantation and discuss the impact of antibodies to 
self-antigens on lung allograft dysfunction.
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Introduction
Over the past 30 years, lung transplantation has become the ultimate treatment for 
patients with end-stage lung disease. The number of lung transplant procedures 
has continued to increase, and more than 3,600 procedures were reported to the 
International Society for Heart and Lung Transplantation (ISHLT) Registry in 2011.1 
Survival after lung transplantation has been slowly improving; however, long-term 
outcomes remain disappointing with a median survival of 6.1 years in the most 
recent era (June 2004 – December 2011).1 This is in contrast to allograft survival 
after kidney and liver transplantation where the median survival is over 9 years after 
deceased-donor kidney transplantation and over 12 years after living-donor kidney 
and deceased-donor liver transplantation.2,3 The major causes of death within the first 
year after lung transplantation are allograft failure and non-cytomegalovirus infec-
tions. Beyond the first year after transplantation, chronic lung allograft dysfunction 





(CLAD), coded in the ISHLT Registry as bronchiolitis or late 
allograft failure, is the leading cause of mortality, accounting 
for .40% of deaths.1 This clearly demonstrates that CLAD 
is the primary obstacle to better long-term outcomes after 
lung transplantation.
It is widely believed that rejection is the underlying cause 
of most forms of CLAD, and traditionally, solid-organ trans-
plant rejection has been regarded as a predominantly T-cell 
mediated process. Accordingly, standard immunosuppressive 
regimens consisting of a calcineurin inhibitor, a cell cycle 
inhibitor, and corticosteroids targeting T-cell proliferation 
and function have made organ transplantation a clinical 
reality.2,3 However, emerging data suggest that humoral 
immunity may play an important and previously underap-
preciated role in rejection and chronic allograft dysfunction. 
Antibody-mediated rejection (AMR) is a widely accepted 
and well-defined form of rejection after kidney and heart 
transplantation, and the Pathology Council of the ISHLT has 
recently proposed a summary statement on the pathology of 
AMR after lung transplantation.4–7 This review will discuss 
the different manifestations of AMR in lung transplantation, 
including hyperacute rejection, acute AMR, donor-specific 
antibodies (DSA) to human leukocyte antigens (HLA), and 
antibodies to self-antigens and their role in the development 
of CLAD.
Hyperacute rejection
Hyperacute rejection results from circulating preexisting 
DSA and occurs within minutes or hours of transplantation 
and perfusion of the allograft. Clinically, hyperacute rejec-
tion after lung transplantation is characterized by fulminant 
allograft dysfunction with severe gas-exchange impairment, 
hemorrhagic pulmonary edema, and diffuse radiographic 
infiltrates.8 Preformed DSA bind to HLA on donor endothe-
lial cells, resulting in the activation of the classical comple-
ment cascade and leading to the formation of the membrane 
attack complex and endothelial cell injury. The development 
and refinement of solid-phase antibody detection assays have 
significantly improved the ability to detect and identify the 
specificity of HLA antibodies before transplantation. Using 
these specificities and the potential donor’s HLA type, cross-
match results can be predicted accurately before donor organ 
acceptance. This virtual crossmatch improves donor selection 
for allosensitized patients and minimizes the risk of HLA 
incompatible transplants; as a result, hyperacute rejection 
has become rare. Nonetheless, hyperacute rejection after 
lung transplantation is a widely accepted form of rejection 
and demonstrates that circulating antibodies can severely 
injure the lung allograft, often resulting in allograft failure. 
The pathology of hyperacute rejection is notable for severe 
acute lung injury with diffuse microvascular thrombi, neutro-
philic infiltration of the alveolar septae, capillaritis, fibrinoid 
necrosis, and hemorrhagic infarction.9–11 Electron micro-
scopy, when performed, demonstrates that endothelial cells 
are the focal point of immunologic injury.12 Furthermore, 
immunostaining for immunoglobulin G or complement 
component 4d (C4d) illustrates an antibody and complement-
mediated endothelial cell injury process.12
Outcomes after hyperacute rejection are generally poor, 
and allograft loss is common. Intensive treatment regimens 
focusing on depleting antibodies or mitigating antibody-medi-
ated injury have been used with mixed results. Bittner et al 
described a case report of successful treatment of hyperacute 
rejection in a single lung transplant recipient with a regimen 
consisting of plasmapheresis, antithymocyte globulin, and 
cyclophosphamide.13 Dawson et al described a case report 
of a bilateral lung transplant recipient who developed hyper-
acute rejection refractory to plasma exchange, rituximab, 
bortezomib, and intravenous immunoglobulin (IVIG) who 
responded well to eculizumab.14 Rituximab, a chimeric mono-
clonal antibody to CD20, a cell-surface antigen expressed on 
mature B-cells, induces B-cell depletion through complement-
dependent cytotoxicity and antibody-dependent cytotoxicity. 
However, plasma cells, the predominant antibody-producing 
cells, do not express CD20; this raises an important poten-
tial limitation to the use of rituximab in AMR. Bortezomib, 
a proteasome inhibitor, induces plasma cell apoptosis and 
offers a theoretical advantage. Eculizumab is a humanized 
monoclonal antibody that targets complement component 
5 (C5) and inhibits the cleavage of C5 into C5a and C5b, 
thereby preventing formation of the membrane attack com-
plex (C5b–C9). This first-in-class complement inhibitor is 
approved for use in paroxysmal nocturnal hemoglobinuria and 
atypical hemolytic uremic syndrome, two uncommon diseases 
of complement dysregulation. Further clinical investigation 
of its use in complement-mediated allograft injury including 
hyperacute rejection and acute AMR is warranted.
Acute AMR
The diagnostic criteria for lung allograft rejection were 
revised in 2007 and classified four forms of rejection: acute 
rejection; lymphocytic bronchiolitis; obliterative bronchiolitis 
(OB); and chronic vascular rejection.15 However, there was 
no consensus on the features or clinicopathologic diagnostic 
criteria for AMR in lung transplant recipients. The National 
Conference to Assess Antibody-Mediated Rejection in Solid 




Perspectives on AMR after lung transplantation
Organ Transplantation has proposed a general paradigm of 
humoral responses applicable to all organs to help facilitate 
further investigation.16 The National Conference defined 
AMR according to the following criteria: circulating DSA; 
C4d deposition; tissue pathology; and clinical allograft 
 dysfunction.16 C4d deposition in lung allografts has been 
demonstrated in cases of AMR; however, it may be non-
specific and can be seen with acute cellular rejection in the 
absence of DSA or other forms of lung injury. Furthermore, 
C4d staining and interpretation is technically difficult to 
perform reliably with reproducible results.17–21 The ISHLT 
Pathology Council summary statement concluded that 
the diagnosis of pulmonary AMR should require: clinical 
allograft dysfunction; circulating DSA; and abnormal histo-
pathologic findings.7 Discussion of C4d staining is included 
in the summary statement, but not required by the ISHLT 
Pathology Council for the diagnosis of pulmonary AMR.7
There have been multiple case reports and case series of 
lung transplant recipients presenting with clinical findings 
consistent with AMR. Early reports included clinical pre-
sentations of allograft dysfunction presenting with diffuse 
alveolar hemorrhage, capillaritis, and/or C4d deposition 
did not identify DSA although less sensitive HLA antibody 
detection assays were used.22,23 In such cases, it is possible 
that DSA may not have be detectable in the peripheral cir-
culation because the antibodies are adsorbed in the allograft. 
Furthermore, non-HLA antibodies against endothelial cells 
were identified in one series and there was clinical improve-
ment with plasmapheresis implying humorally mediated 
injury as the mechanism of allograft dysfunction.23 In addi-
tion, this does not rule out the possibility that some of the anti-
bodies may have been autoantibodies and autoimmunity has 
emerged as a risk factor for chronic allograft dysfunction.24 
The role of autoimmunity in acute and chronic allograft 
dysfunction will be discussed in “Role of autoimmunity 
and antibodies to self-antigens in primary graft dysfunction 
and CLAD”.
Subsequently, two case reports from independent cen-
ters described similar clinicopathological features of acute 
AMR.25,26 In both cases, the recipient was not allosensitized 
prior to transplantation and had a negative direct crossmatch 
at the time of transplant. Both developed allograft dysfunction, 
capillaritis, C4d deposition, and new circulating DSA. In the 
first case, there was no response to high dose corticosteroids 
and basiliximab, but there was a good response to rituximab.25 
The second patient was treated with a combination of IVIG, 
plasmapheresis, and rituximab with resolution of the allograft 
dysfunction and long-term clinical stability.26
In 2013, our center reported a case series of patients with 
AMR and proposed a strict definition of acute AMR in lung 
transplant recipients.27 This definition was based on criteria 
proposed by the ISHLT Pathology Council and the National 
Conference to Assess Antibody-Mediated Rejection in 
Solid Organ Transplantation. We defined acute AMR as: 
allograft dysfunction; circulating DSA; tissue pathology; 
and capillary endothelial C4d deposition (Figure 1). We 
conducted a retrospective cohort study at our center that 
included 501 lung transplant procedures from January 1, 
2004–June 30, 2012. During that time, we identified 21 lung 
recipients meeting this stringent definition of acute AMR. 
All patients had diffuse, bilateral pulmonary infiltrates on 
imaging and other causes of acute allograft dysfunction were 
ruled out (Figure 2). The predominant pathology was acute 
lung injury, and eleven of the 21 patients had capillaritis 
while ten did not.
Based on the definition to identify cases, capillary 
endothelial C4d deposition was seen in all patients. AMR 
was diagnosed a median of 258 days after transplantation, 
14 in the first year and the other seven more than 1 year after 
transplant. Also, 14 of the 21 patients required mechanical 
ventilation, and six died of refractory AMR during their index 
hospitalization. Of the 15 patients who survived their index 
episode of AMR, one had preexisting CLAD and 13 of the 
remaining 14 developed CLAD. Nine of the 15 patients who 
survived their index episode of acute AMR died during the 
follow-up period. Recipients who cleared the DSA had a 
better survival than those with persistent DSA.
During the study period, our treatment regimens were 
individualized, and the specific treatment depended on the 
clinical course; these included antithymocyte globulin, IVIG, 
plasmapheresis, rituximab, bortezomib, and/or eculizumab 
in various combinations. The high mortality and near uni-
versal development of CLAD among survivors in this cohort 
Figure 1 Pathologic findings in patient with acute pulmonary AMR.
Notes: (A) Transbronchial biopsy specimen from a patient with acute AMR 
demonstrating capillaritis (arrows with solid lines) and hyaline membrane formation 
(arrow with dotted line). Original magnification 400×. (B) Transbronchial biopsy 
specimen from a patient with acute AMR demonstrating circumferential C4d staining 
of the capillary endothelium (arrows). Original magnification 600×.
Abbreviations: AMR, antibody-mediated rejection; C4d, component 4d.





underscore the significant clinical impact of acute AMR in 
lung transplant recipients.
The optimal treatment regimen for patients with acute AMR 
is not currently known. Given the lack of a widely accepted 
definition of acute AMR after lung transplantation, it is difficult 
to determine from the published literature whether reported 
cases all had the same syndrome of allograft dysfunction. 
Furthermore, treatment in all cases and series has been indi-
vidualized and highly dependent on the clinical course. This 
makes comparing the relative efficacy of different regimens 
impossible. Nonetheless, different combinations of plasma-
pheresis, IVIG, rituximab, antithymocyte globulin, bortezomib, 
and eculizumab have been given to treat pulmonary AMR.27–31 
There is immunological rationale for combination therapy, 
including inhibiting DSA-mediated complement activation with 
eculizumab, depleting circulating DSA with plasmapheresis, 
decreasing antibody production by targeting plasma cells with 
bortezomib, and decreasing plasma cell development and 
activation with rituximab. These more targeted therapies are 
likely to be given in combination with therapies with broader 
spectrums of activity, including IVIG, high-dose corticoster-
oids, and antithymocyte globulin. Which of these therapies 
or combinations of therapies is most effective remains to be 
determined and will require randomized controlled trials with 
a strict definition of acute AMR in the future.
A multidisciplinary ISHLT working group, consisting of 
experts in pulmonary medicine, pathology, and immunology 
is currently reviewing the published literature and profes-
sional experiences to develop a definition for AMR after lung 
transplantation. This will standardize the nomenclature and 
facilitate the necessary clinical and immunological research 
to better understand AMR and ultimately identify effective 
preventative and treatment strategies.
DSA and CLAD
Traditionally, OB has been the histologic hallmark of chronic 
lung allograft rejection. However, histologic confirmation of 
OB is difficult because of the patchy nature of the disease 
and the small samples obtained with transbronchial lung 
biopsies, so bronchiolitis obliterans syndrome (BOS), 
defined and staged according to changes in spirometry, has 
served as the clinical surrogate for OB. More recently, there 
has been a paradigm shift with the introduction of the more 
encompassing term “chronic lung allograft dysfunction,” 
which includes BOS and restrictive allograft syndrome 
(RAS).32 There has been a strong association between DSA 
and BOS, but it remains unclear if DSA play a role in RAS 
development.
An association between the development of HLA antibod-
ies and BOS has been recognized since the late 1990s, and 
more recent clinical data linked HLA antibodies, and DSA in 
particular, with persistent and high-grade acute cellular rejec-
tion and lymphocytic bronchiolitis.33–37 In addition, a recent 
large cohort analysis identified the development of HLA 
antibodies as an independent risk factor for mortality after 
transplant.38 Despite these clinical data, it remains unclear if 
HLA antibodies cause BOS or if they are an epiphenomenon 
of the cellular immune response. However, in vitro and ani-
mal studies suggest that HLA (and major histocompatibility 
complex [MHC]) antibodies play a pathogenic role; HLA 
antibodies have been shown to induce airway epithelial cell 
proliferation, lead to the release of fibrogenic growth factors, 
and result in epithelial cell apoptosis.39 Additionally, MHC 
antibodies have been shown to induce airway obliteration 
when systemically administered in a murine heterotopic 
tracheal transplant model and cause small airway obliteration 
when delivered intrabronchially into native lungs.40,41 Given 
the experimental and clinical data suggesting a role for HLA 
antibodies in the development of BOS and CLAD, there has 
been an intensified focus on the role of these antibodies in 
lung transplant recipients.
Our center examined the outcomes of lung transplant 
recipients who developed DSA and the response to treatment 
with either IVIG or IVIG and rituximab.37 In this series of 
116 recipients, 65 (56%) developed de novo DSA during the 
study period. There was no statistically significant difference 
in the incidence of acute cellular rejection, lymphocytic 
bronchiolitis, or BOS between those who developed DSA and 
were treated and those who did not develop DSA. However, 
since this was not a randomized controlled trial, it is not 
clear if this finding reflects a treatment effect. Nonetheless, 
this study demonstrated that patients who had successful 
depletion of DSA (ie, DSA was no longer detectable after 
treatment) had greater freedom from BOS and better survival 
than those who had persistent DSA.
Figure 2 Radiological findings in patient with acute pulmonary AMR.
Notes: (A) Diffuse bilateral infiltrates on chest radiograph in a lung recipient 
with acute AMR. (B) Bilateral infiltrates with ground-glass opacities on computed 
tomography of the chest in the same lung recipient with AMR.
Abbreviation: AMR, antibody-mediated rejection.
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In a recent large single center cohort study, DSA develop-
ment was a significant risk factor for mortality but not BOS.38 
In contrast, non-DSA HLA antibodies were significant risk 
factors for both BOS and mortality.38 Reasons for the lack 
of association between DSA and BOS in this study are not 
clear, but the results demonstrate that non-DSA HLA antibod-
ies can also increase the risk of BOS. In fact, pretransplant 
non-DSA HLA antibodies and major histocompatibility 
complex (MHC) class I-related chain A antibodies have been 
associated with an increased risk of BOS.42 Clearly, addi-
tional studies and randomized controlled trials are needed to 
better understand the role of HLA and non-HLA antibodies 
in BOS development and to critically examine the potential 
benefit of DSA depletion in clinically stable lung transplant 
recipients. Of note, a multicenter randomized controlled trial 
examining the efficacy of rituximab as induction immuno-
suppression in pediatric lung transplant recipients is being 
planned by the Clinical Trials in Organ Transplantation in 
Children network.
In addition, since CLAD is the leading cause of death 
beyond the first year after lung transplantation and its 
pathogenesis remains unclear, further investigation into the 
potential role of DSA in the development of a chronic form 
of AMR is indicated. It is possible that RAS may represent 
chronic AMR; however, data linking RAS to humoral 
immune responses are lacking to date. Clearly, this is an area 
of ongoing investigation.
Role of autoimmunity and antibodies 
to self-antigens in primary graft 
dysfunction and CLAD
Autoimmunity is the hallmark of systemic autoimmune 
diseases, such as rheumatoid arthritis, systemic lupus ery-
thematosus, and the vasculitides. Many of these diseases 
are thought to result from a loss of immunologic tolerance 
and the development of immune responses to self-antigens.43 
Antibodies to myosin, vimentin, and heat-shock proteins after 
heart transplantation and to angiotensin type 1 receptor after 
kidney transplantation have been associated with allograft 
dysfunction.44–47 More recent studies have demonstrated a 
potential role for autoimmunity in both primary graft dys-
function and BOS. For example, peripheral blood mononu-
clear cells taken from lung transplant recipients have been 
found to be reactive against self-antigens, demonstrating the 
presence of T-cell mediated autoimmunity.48
The two self-antigens that have received the most 
attention in lung transplant recipients are type V collagen 
(Col V) and K-α 1 tubulin. Col V and K-α 1 tubulin are 
both expressed on airway epithelial cells, and antibod-
ies against these self-antigens have been associated with 
primary graft dysfunction and BOS.49–51 Furthermore, 
the development of DSA has been associated with the 
development of antibodies to self-antigens, and it has been 
proposed that alloimmune responses in the form of DSA 
may induce an autoimmune response and contribute to the 
pathogenesis of BOS.52 It has also been demonstrated that 
lung transplant recipients who were treated with antibody-
directed therapy and cleared the antibodies to self-antigens 
are significantly less likely to develop BOS compared to 
those who had persistent antibodies to self-antigens.24 The 
precise mechanism by which autoimmunity contributes 
to acute and chronic allograft dysfunction and how to use 
these emerging data clinically remains an area of ongoing 
investigation.
Conclusion
CLAD remains the major cause of death in lung transplant 
recipients beyond the first year after transplantation. Although 
T-cell inhibition has been the primary goal of immunosup-
pression to prevent allograft rejection, it is becoming increas-
ingly evident that AMR and the development of DSA and 
subsequent CLAD play a significant role in allograft and 
patient survival. Additionally, antibodies to self-antigens 
appear to play a role in the development of CLAD. As the 
understanding of the pathophysiology and clinical science 
advances, further investigations into treatment strategies for 
antibody depletion and immune modulation will be possible. 
This is crucial to identify strategies to improve outcomes 
after lung transplantation.
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